玻璃体内阿柏西普8mg治疗新生血管性年龄相关性黄斑变性:随机3期PULSAR试验96周结果
PULSAR试验96周结果显示,新生血管性年龄相关性黄斑变性患者接受阿柏西普8mg每12周或每16周给药,在96周时最佳矫正视力变化非劣效于阿柏西普2mg每8周,且安全性相似。
要点
- 阿柏西普8mg每12周或每16周组96周最佳矫正视力变化非劣效于2mg每8周组。
- 8mg组约87%(每12周组)维持≥12周间隔,每16周组78%达≥16周间隔。
- 三组眼部治疗中出现的不良事件发生率相似。
核心结论
- 阿柏西普8mg在新生血管性年龄相关性黄斑变性患者中维持疾病控制至96周,视觉和解剖学改善得以维持,且给药间隔延长,安全性特征与阿柏西普2mg相似。
研究设计与样本
- 3期、随机、非劣效性、96周试验,纳入1009例未接受过治疗的50岁及以上新生血管性年龄相关性黄斑变性患者,按1:1:1随机分配至阿柏西普8mg每12周、8mg每16周或2mg每8周组,初始3次每月给药后,8mg组根据预设标准调整给药间隔。
主要发现
- 96周时最佳矫正视力最小二乘均值变化:8mg每12周组+5.6字母(95%CI 4.1-7.1),8mg每16周组+5.5字母(95%CI 4.0-7.0),2mg每8周组+6.6字母(95%CI 5.2-8.0);8mg每12周和每16周组与2mg每8周组的差异满足48周主要终点规定的非劣效性标准。
- 中央视网膜厚度平均(标准差)变化:8mg每12周组-143.9(123.6)μm,8mg每16周组-153.4(140.8)μm,2mg每8周组-135.8(133.1)μm。
- 完成96周治疗的患者中,8mg每12周组、8mg每16周组和2mg每8周组分别平均接受9.7、8.2和12.8次活性注射。
- 8mg每12周组87%患者最后分配给药间隔≥12周;8mg每16周组分别有78%、53%和31%患者符合最后分配间隔≥16周、≥20周和24周。
- 眼部治疗中出现的不良事件发生率各组相似。
关键数值与推荐
- 96周最佳矫正视力变化非劣效性标准参照48周主要终点预设标准,8mg每12周和每16周组与2mg每8周组的差异均满足该标准。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report the efficacy, durability, and safety of intravitreal aflibercept 8 mg versus intravitreal aflibercept 2 mg every 8 weeks (2q8) in patients with neovascular age-related macular degeneration (nAMD) through 96 weeks, PULSAR (ClinicalTrials.gov identifier, NCT04423718). DESIGN: Phase 3, randomized, noninferiority, 96-week trial. PARTICIPANTS: Treatment-naive adults ≥ 50 years with nAMD. METHODS: Patients were randomized 1:1:1 to intravitreal aflibercept 8 mg every 12 or 16 weeks (8q12 or 8q16), or 2q8, after 3 initial monthly doses; dosing intervals in 8-mg groups were modified based on prespecified criteria. MAIN OUTCOME MEASURES: Change from baseline in best-corrected visual acuity (BCVA) and central retinal thickness (CRT), proportion of patients maintaining or extending the randomized dosing intervals, and safety outcomes. RESULTS: Of 1009 patients treated, 869 patients (8q12, n = 291; 8q16, n = 292; 2q8, n = 286) completed treatment through week 96. Least squares (LS) mean change from baseline in BCVA at week 96 was +5.6 (95% confidence interval [Cl], 4.1-7.1), +5.5 (95% Cl, 4.0-7.0), and +6.6 (95% Cl, 5.2-8.0) letters in the 8q12, 8q16, and 2q8 groups, respectively; 8q12 and 8q16 differences versus 2q8 in LS mean BCVA changes at week 96 met the noninferiority criteria specified for the primary end point at week 48. Mean (standard deviation) change in CRT from baseline was -143.9 (123.6) μm, -153.4 (140.8) μm, and -135.8 (133.1) μm in the 8q12, 8q16, and 2q8 groups, respectively. Patients completing 96 weeks of treatment in the 8q12, 8q16, and 2q8 groups received a mean of 9.7, 8.2, and 12.8 active injections, respectively. Of these, 87% of patients in the 8q12 group had last assigned dosing intervals of 12 weeks or more, whereas 78%, 53%, and 31% of patients in the 8q16 group qualified for last assigned dosing intervals of ≥ 16 weeks, ≥ 20 weeks, and 24 weeks, respectively. Incidence of ocular treatment-emergent adverse events was similar across groups. CONCLUSIONS: Aflibercept 8 mg delivered sustained disease control in patients with nAMD, maintaining improvements in visual and anatomic outcomes through week 96 with extended dosing intervals and similar safety profile to aflibercept 2 mg. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
引用
- Korobelnik JF, Lanzetta P, Leal S, et al. Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial. Ophthalmology. 2025. PMID: 40876598. doi:10.1016/j.ophtha.2025.08.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。